World’s first long-term CGM system to be integrated with world’s leading diabetes management platform
GERMANTOWN, MD, June 10, 2018– Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced a partnership with Glooko, Inc, the leading diabetes data management company. The partnership enables integration of the long-term Eversense® branded continuous glucose monitoring (CGM) systems with Glooko’s diabetes data management platform.
The integration of these solutions will allow Eversense CGM data to be synced into Glooko’s platform directly from the Senseonics cloud. Eversense users will be able to view historical glucose and related data both in Glooko’s Mobile and Web Apps and will continue to get real-time readings from their Eversense Mobile Application. Healthcare professionals may view their patients’ data in the Glooko Population Tracker in interactive reports alongside other data resident in Glooko.
“With this integration, users can consolidate their glucose data with insulin, meals, medication and exercise to help them see glycemic patterns more readily. Glooko allows our users to take full advantage of both companies’ platforms and the large amount of data from our Eversense® and Eversense® XL systems” said Dr. Tim Goodnow, President and CEO of Senseonics. “Partnering with an innovative platform like Glooko fits with our strategy of giving people the tools to use all of their health data to conveniently and confidently make actionable lifestyle decisions.”
For Glooko, the integration of the Eversense systems is the first long-term sensor that will be compatible with their intelligent digital health platform. Users of the Eversense systems will have the opportunity to see how their glucose levels change over the long term without having to estimate the impact of frequent sensor changeovers and warm-up periods.
“We are thrilled to add Senseonics’ breakthrough Eversense and Eversense XL CGM data to our platform so that people with diabetes and clinicians can access this valuable data in context in our reports online and via mobile,“ said Russ Johannesson, Glooko’s CEO. He continued, “Our cloud integration with Senseonics gives users easy access to their glucose data from the sensor, enabling them to make decisions based on their glucose patterns.”
The Eversense system has been integrated with Diasend in the EU since 2017. The companies expect implementation of the Eversense/Glooko data integration to be by the end of the year. Learnings from this partnership will benefit both organizations as they expand into insulin titration and decision support tools.
This global agreement covers all markets where Glooko and the Eversense Systems are currently available.
Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ first generation continuous glucose monitoring (CGM) system, Eversense®, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.